New  ||| S:0 E:4 ||| JJ
oral  ||| S:4 E:9 ||| JJ
anticoagulants  ||| S:9 E:24 ||| NN
for  ||| S:24 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
prevention  ||| S:32 E:43 ||| NN
of  ||| S:43 E:46 ||| IN
thromboembolism  ||| S:46 E:62 ||| NN
in  ||| S:62 E:65 ||| IN
atrial  ||| S:65 E:72 ||| JJ
fibrillation ||| S:72 E:84 ||| NN
:  ||| S:84 E:86 ||| :
from  ||| S:86 E:91 ||| IN
clinical  ||| S:91 E:100 ||| JJ
evidence  ||| S:100 E:109 ||| NN
to  ||| S:109 E:112 ||| TO
appropriate  ||| S:112 E:124 ||| JJ
use  ||| S:124 E:128 ||| NN
The  ||| S:128 E:132 ||| DT
large  ||| S:132 E:138 ||| JJ
amount  ||| S:138 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
data  ||| S:148 E:153 ||| NNS
on  ||| S:153 E:156 ||| IN
new  ||| S:156 E:160 ||| JJ
oral  ||| S:160 E:165 ||| JJ
anticoagulants  ||| S:165 E:180 ||| JJ
deriving  ||| S:180 E:189 ||| NN
from  ||| S:189 E:194 ||| IN
the  ||| S:194 E:198 ||| DT
RE-LY ||| S:198 E:203 ||| JJ
,  ||| S:203 E:205 ||| ,
ROCKET  ||| S:205 E:212 ||| NNP
AF  ||| S:212 E:215 ||| NNP
and  ||| S:215 E:219 ||| CC
ARISTOTLE  ||| S:219 E:229 ||| NNP
studies ||| S:229 E:236 ||| NNS
,  ||| S:236 E:238 ||| ,
the  ||| S:238 E:242 ||| DT
analysis  ||| S:242 E:251 ||| NN
of  ||| S:251 E:254 ||| IN
patient  ||| S:254 E:262 ||| JJ
subgroups  ||| S:262 E:272 ||| NNS
and  ||| S:272 E:276 ||| CC
the  ||| S:276 E:280 ||| DT
latest  ||| S:280 E:287 ||| JJS
guidelines  ||| S:287 E:298 ||| NNS
on  ||| S:298 E:301 ||| IN
atrial  ||| S:301 E:308 ||| JJ
fibrillation  ||| S:308 E:321 ||| NNS
( ||| S:321 E:322 ||| -LRB-
AF ||| S:322 E:324 ||| NNP
)  ||| S:324 E:326 ||| -RRB-
issued  ||| S:326 E:333 ||| VBN
by  ||| S:333 E:336 ||| IN
the  ||| S:336 E:340 ||| DT
major  ||| S:340 E:346 ||| JJ
international  ||| S:346 E:360 ||| JJ
cardiology  ||| S:360 E:371 ||| JJ
societies  ||| S:371 E:381 ||| NNS
created  ||| S:381 E:389 ||| VBD
the  ||| S:389 E:393 ||| DT
need  ||| S:393 E:398 ||| NN
for  ||| S:398 E:402 ||| IN
this  ||| S:402 E:407 ||| DT
special  ||| S:407 E:415 ||| JJ
issue ||| S:415 E:420 ||| NN
.  ||| S:420 E:422 ||| .
Regulatory  ||| S:422 E:433 ||| JJ
approval  ||| S:433 E:442 ||| NN
and  ||| S:442 E:446 ||| CC
reimbursement  ||| S:446 E:460 ||| NN
within  ||| S:460 E:467 ||| IN
the  ||| S:467 E:471 ||| DT
National  ||| S:471 E:480 ||| NNP
Healthcare  ||| S:480 E:491 ||| NNP
System  ||| S:491 E:498 ||| NNP
of  ||| S:498 E:501 ||| IN
these  ||| S:501 E:507 ||| DT
new  ||| S:507 E:511 ||| JJ
oral  ||| S:511 E:516 ||| JJ
anticoagulants  ||| S:516 E:531 ||| NN
for  ||| S:531 E:535 ||| IN
patients  ||| S:535 E:544 ||| NNS
with  ||| S:544 E:549 ||| IN
AF  ||| S:549 E:552 ||| NNP
at  ||| S:552 E:555 ||| IN
risk  ||| S:555 E:560 ||| NN
of  ||| S:560 E:563 ||| IN
stroke  ||| S:563 E:570 ||| NNS
are  ||| S:570 E:574 ||| VBP
expected  ||| S:574 E:583 ||| VBN
to  ||| S:583 E:586 ||| TO
progressively  ||| S:586 E:600 ||| RB
modify  ||| S:600 E:607 ||| VB
anticoagulant  ||| S:607 E:621 ||| JJ
therapy  ||| S:621 E:629 ||| NN
for  ||| S:629 E:633 ||| IN
most  ||| S:633 E:638 ||| JJS
patients  ||| S:638 E:647 ||| NNS
on  ||| S:647 E:650 ||| IN
warfarin  ||| S:650 E:659 ||| JJ
treatment ||| S:659 E:668 ||| NN
.  ||| S:668 E:670 ||| .
This  ||| S:670 E:675 ||| DT
evolution  ||| S:675 E:685 ||| NN
in  ||| S:685 E:688 ||| IN
the  ||| S:688 E:692 ||| DT
therapeutic  ||| S:692 E:704 ||| JJ
approach  ||| S:704 E:713 ||| NN
to  ||| S:713 E:716 ||| TO
AF  ||| S:716 E:719 ||| NNP
is  ||| S:719 E:722 ||| VBZ
primarily  ||| S:722 E:732 ||| RB
driven  ||| S:732 E:739 ||| VBN
by  ||| S:739 E:742 ||| IN
the  ||| S:742 E:746 ||| DT
improved  ||| S:746 E:755 ||| JJ
efficacy  ||| S:755 E:764 ||| NN
and  ||| S:764 E:768 ||| CC
safety  ||| S:768 E:775 ||| NN
profile  ||| S:775 E:783 ||| NN
of  ||| S:783 E:786 ||| IN
these  ||| S:786 E:792 ||| DT
novel  ||| S:792 E:798 ||| NN
agents  ||| S:798 E:805 ||| NNS
that  ||| S:805 E:810 ||| IN
results  ||| S:810 E:818 ||| NNS
in  ||| S:818 E:821 ||| IN
reduced  ||| S:821 E:829 ||| JJ
thromboembolic  ||| S:829 E:844 ||| NN
and  ||| S:844 E:848 ||| CC
bleeding  ||| S:848 E:857 ||| VBG
risk ||| S:857 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
in  ||| S:863 E:866 ||| IN
addition  ||| S:866 E:875 ||| NN
to  ||| S:875 E:878 ||| TO
their  ||| S:878 E:884 ||| PRP$
ease  ||| S:884 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
administration  ||| S:892 E:907 ||| NN
and  ||| S:907 E:911 ||| CC
freedom  ||| S:911 E:919 ||| NN
from  ||| S:919 E:924 ||| IN
laboratory  ||| S:924 E:935 ||| NN
monitoring ||| S:935 E:945 ||| NN
.  ||| S:945 E:947 ||| .
When  ||| S:947 E:952 ||| WRB
anticoagulation  ||| S:952 E:968 ||| NN
is  ||| S:968 E:971 ||| VBZ
indicated ||| S:971 E:980 ||| VBN
,  ||| S:980 E:982 ||| ,
it  ||| S:982 E:985 ||| PRP
is  ||| S:985 E:988 ||| VBZ
currently  ||| S:988 E:998 ||| RB
suggested  ||| S:998 E:1008 ||| VBN
to  ||| S:1008 E:1011 ||| TO
replace  ||| S:1011 E:1019 ||| VB
dose-adjusted  ||| S:1019 E:1033 ||| JJ
warfarin  ||| S:1033 E:1042 ||| NN
with  ||| S:1042 E:1047 ||| IN
one  ||| S:1047 E:1051 ||| CD
of  ||| S:1051 E:1054 ||| IN
the  ||| S:1054 E:1058 ||| DT
new  ||| S:1058 E:1062 ||| JJ
oral  ||| S:1062 E:1067 ||| JJ
anticoagulants ||| S:1067 E:1081 ||| NN
.  ||| S:1081 E:1083 ||| .
Although  ||| S:1083 E:1092 ||| IN
no  ||| S:1092 E:1095 ||| DT
data  ||| S:1095 E:1100 ||| NNS
from  ||| S:1100 E:1105 ||| IN
comparative  ||| S:1105 E:1117 ||| JJ
studies  ||| S:1117 E:1125 ||| NNS
among  ||| S:1125 E:1131 ||| IN
new  ||| S:1131 E:1135 ||| JJ
anticoagulants  ||| S:1135 E:1150 ||| NNS
are  ||| S:1150 E:1154 ||| VBP
available ||| S:1154 E:1163 ||| JJ
,  ||| S:1163 E:1165 ||| ,
the  ||| S:1165 E:1169 ||| DT
assessment  ||| S:1169 E:1180 ||| NN
of  ||| S:1180 E:1183 ||| IN
their  ||| S:1183 E:1189 ||| PRP$
efficacy  ||| S:1189 E:1198 ||| NN
and  ||| S:1198 E:1202 ||| CC
safety  ||| S:1202 E:1209 ||| NN
profile  ||| S:1209 E:1217 ||| NN
will  ||| S:1217 E:1222 ||| MD
help  ||| S:1222 E:1227 ||| VB
clinicians  ||| S:1227 E:1238 ||| VBN
to  ||| S:1238 E:1241 ||| TO
tailor  ||| S:1241 E:1248 ||| VB
therapy  ||| S:1248 E:1256 ||| NN
to  ||| S:1256 E:1259 ||| TO
individual  ||| S:1259 E:1270 ||| JJ
patients  ||| S:1270 E:1279 ||| NNS
by  ||| S:1279 E:1282 ||| IN
choosing  ||| S:1282 E:1291 ||| VBG
the  ||| S:1291 E:1295 ||| DT
most  ||| S:1295 E:1300 ||| RBS
effective  ||| S:1300 E:1310 ||| JJ
drug  ||| S:1310 E:1315 ||| NN
at  ||| S:1315 E:1318 ||| IN
the  ||| S:1318 E:1322 ||| DT
appropriate  ||| S:1322 E:1334 ||| JJ
dosage ||| S:1334 E:1340 ||| NN
.  ||| S:1340 E:1342 ||| .
This  ||| S:1342 E:1347 ||| DT
review  ||| S:1347 E:1354 ||| NN
describes  ||| S:1354 E:1364 ||| VBZ
different  ||| S:1364 E:1374 ||| JJ
algorithms  ||| S:1374 E:1385 ||| NN
for  ||| S:1385 E:1389 ||| IN
the  ||| S:1389 E:1393 ||| DT
use  ||| S:1393 E:1397 ||| NN
of  ||| S:1397 E:1400 ||| IN
new  ||| S:1400 E:1404 ||| JJ
oral  ||| S:1404 E:1409 ||| JJ
anticoagulants  ||| S:1409 E:1424 ||| NN
in  ||| S:1424 E:1427 ||| IN
everyday  ||| S:1427 E:1436 ||| JJ
clinical  ||| S:1436 E:1445 ||| JJ
practice ||| S:1445 E:1453 ||| NN
,  ||| S:1453 E:1455 ||| ,
also  ||| S:1455 E:1460 ||| RB
in  ||| S:1460 E:1463 ||| IN
AF  ||| S:1463 E:1466 ||| NNP
patients  ||| S:1466 E:1475 ||| NNS
with  ||| S:1475 E:1480 ||| IN
concomitant  ||| S:1480 E:1492 ||| JJ
renal  ||| S:1492 E:1498 ||| JJ
dysfunction ||| S:1498 E:1509 ||| NN
,  ||| S:1509 E:1511 ||| ,
with  ||| S:1511 E:1516 ||| IN
a  ||| S:1516 E:1518 ||| DT
special  ||| S:1518 E:1526 ||| JJ
focus  ||| S:1526 E:1532 ||| NN
on  ||| S:1532 E:1535 ||| IN
drug  ||| S:1535 E:1540 ||| NN
interactions  ||| S:1540 E:1553 ||| NNS
and  ||| S:1553 E:1557 ||| CC
bleeding  ||| S:1557 E:1566 ||| VBG
risk ||| S:1566 E:1570 ||| NN
.  ||| S:1570 E:1572 ||| .
